Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2007010235) ETHANOLAMINE SALT OF N- (3-METHOXY-5-METHYLPYRAZIN-2YL) -2- (4- [1 , 3 , 4-0XADIAZ0LE-2-YL] PHENYL) PYRIDINE-3- SULPHONAMIDE
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

Claims

1. N-(3-Methoxy-5-methylpyrazin-2-yl)-2-(4-[l,3,4-oxadiazol-2-yl]phenyl)pyridine-3- sulphonamide ethanolamine salt.
5
2. The salt according to claim 1, further characterized in that the compound is in substantially crystalline form.

3. The salt according to claim 2, further characterized in that the compound has an X-ray 10 powder diffraction pattern containing at least peaks with 2-theta values at 8.9°, 10.9° and 18° measured using CuKa radiation.

4. The salt according to claim 3, further characterized in that the compound has an X-ray powder diffraction pattern containing at least peaks with 2-theta values at 8.9°, 10.9°, 18°, 25.5°,

15 15.5° and 21.7° measured using CuKa radiation.

5. The salt according to claim 4, further characterized in that the compound has an X-ray powder diffraction pattern containing at least peaks with 2-theta values at 8.9°, 10.9°, 18°, 25.5°, 15.5°, 21.7, 21.2°, 24.1° and 25.9° measured using CuKa radiation.
20
6. A compound according to claim 5, characterized by an X ray diffraction pattern essentially as defined in Table 3 and/or in Figure 3.

7. A process for the preparation of N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[l,3,4-25 oxadiazol-2-yl]phenyl)pyridine-3 -sulphonamide which comprises the use of ethanolamine to deprotect a compound of formula (II):



(II)
where Pg is a suitable nitrogen protecting group.

8. The process according to claim 7 wherein Pg is isobutoxycarbonyl.

9. A process for the manufacture of N-(3-methoxy-5-methylρyrazin-2-yl)-2-(4-[l,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide substantially in the form of Form 1 which comprises:
(i) the use of ethanolamine to deprotect a compound of formula (II):



(H)
where Pg is a suitable nitrogen protecting group; followed by
(ii) the addition of the resulting N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[l,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide ethanolamine salt to an acid.

10. The process according to claim 9 wherein Pg is isobutoxycarbonyl.

11. The process according to claim 9 or claim 10 wherein the acid is acetic acid.

12. The use of the salt according to claim 1 in the preparation of N-(3-methoxy-5- methylpyrazin-2-yl)-2-(4-[l,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide.
5
13. The use of the salt according to claim 1 in the manufacture of N-(3-methoxy-5- methylpyrazin-2-yl)-2-(4-[l,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide substantially in the form of Foπn 1.

10 14. A pharmaceutical composition which comprises the salt according to any one of claims 1 - 6 in association with a pharmaceutically acceptable diluent or carrier.

15. The use of the salt according to any one of claims 1-6 as a medicament.

15 16. The use of the salt according to any one of claims 1 -6, in the manufacture of a medicament for use in the treatment of cancer in a warm blooded animal such as man.

17. The use according to claim 16 wherein the cancer is oesophageal cancer, myeloma, hepatocellular, pancreatic, cervical cancer, ewings tumour, neuroblastoma, Kaposis sarcoma,

20 ovarian cancer, breast cancer, colorectal cancer, prostate cancer, bladder cancer, melanoma, lung cancer - non small cell lung cancer, and small cell lung cancer, gastric cancer, head and neck cancer, renal cancer lymphoma and leukaemia.

18. The use according to claim 16 wherein the cancer is prostate cancer.
25
19. The use according to any one of claims 16-18 wherein the cancer is in a metastatic state.

20. The use according to any one of claims 16-18 wherein the cancer is in a non-metastatic state.
30

21. The use according to claim 16 wherein the cancer is renal, thyroid, lung, breast or prostate cancer that is producing bone metastases.

22. A method of treating cancer which comprises administering an effective amount of the 5 salt according to claim 1, to a warm blooded animal such as man.

23. The method according to claim 22 wherein the cancer is oesophageal cancer, myeloma, hepatocellular, pancreatic, cervical cancer, ewings tumour, neuroblastoma, Kaposis sarcoma, ovarian cancer, breast cancer, colorectal cancer, prostate cancer, bladder cancer, melanoma, lung

10 cancer - non small cell lung cancer, and small cell lung cancer, gastric cancer, head and neck cancer, renal cancer lymphoma and leukaemia.

24. The method according to claim 22 wherein the cancer is prostate cancer.

15 25. The method according to claim 22 wherein the cancer is in a metastatic state.

26. The method according to claim 23 wherein the cancer is in a metastatic state.

27. The method according to claim 24 wherein the cancer is in a metastatic state.
20
28. The method according to claim 22 wherein the cancer is in a non-metastatic state.

29. The method according to claim 23 wherein the cancer is in a non-metastatic state.

25 30. The method according to claim 24 wherein the cancer is in a non-metastatic state.

31. The method according to claim 22 wherein the cancer is renal, thyroid, lung, breast or prostate cancer that is producing bone metastases.